Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1)
- PMID: 26432912
- DOI: 10.1016/j.vaccine.2015.09.056
Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1)
Abstract
The ability to induce a broadly neutralizing antibody (bNAb) response following vaccination is regarded as a crucial aspect in developing an effective vaccine against human immunodeficiency virus type 1 (HIV-1). The bNAbs target the HIV-1 envelope glycoprotein (Env) which is exposed on the virus surface, thereby preventing cell entry. To date, conventional vaccine approaches such as the use of Env-based immunogens have been unsuccessful. We expressed, purified, characterized and evaluated the immunogenicity of several unique HIV-1 subtype C Env immunogens in small animals. Here we report that vaccine immunogens based on Env liganded to a two domain CD4 variant, 2dCD4(S60C) are capable of consistently eliciting potent, broadly neutralizing antibody responses in New Zealand white rabbits against a panel of clinically relevant HIV-1 pseudoviruses. This was irrespective of the Env protein subtype and context. Importantly, depletion of the anti-CD4 antibodies appeared to abrogate the neutralization activity in the rabbit sera. Taken together, this data suggests that the Env-2dCD4(S60C) complexes described here are "super" immunogens, and potentially immunofocus antibody responses to a unique epitope spanning the 2dCD4(60C). Recent data from the two available anti-CD4 monoclonal antibodies, Ibalizumab and CD4-Ig (and bispecific variants thereof) have highlighted that the use of these broad and potent entry inhibitors could circumvent the need for a conventional vaccine targeting HIV-1. Overall, the ability of the unique Env-2dCD4(S60C) complexes to elicit potent bNAb responses has not been described previously, reinforcing that further investigation for their utility in preventing and controlling HIV-1/SIV infection is warranted.
Keywords: Anti-CD4 responses; Broadly neutralizing antibodies; Env–2dCD4(S60C); HIV-1 vaccine immunogens; Preclinical testing.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits.Vaccine X. 2022 Sep 30;12:100222. doi: 10.1016/j.jvacx.2022.100222. eCollection 2022 Dec. Vaccine X. 2022. PMID: 36262212 Free PMC article.
-
HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.Expert Rev Vaccines. 2016;15(3):349-65. doi: 10.1586/14760584.2016.1129905. Epub 2016 Jan 8. Expert Rev Vaccines. 2016. PMID: 26654478 Review.
-
Covalent binding of human two-domain CD4 to an HIV-1 subtype C SOSIP.664 trimer modulates its structural dynamics.Biochem Biophys Res Commun. 2022 Jul 5;612:181-187. doi: 10.1016/j.bbrc.2022.04.101. Epub 2022 Apr 26. Biochem Biophys Res Commun. 2022. PMID: 35550505
-
Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.J Virol. 2015 Dec 30;90(6):2740-55. doi: 10.1128/JVI.02380-15. J Virol. 2015. PMID: 26719262 Free PMC article.
-
Strategies for inducing effective neutralizing antibody responses against HIV-1.Expert Rev Vaccines. 2019 Nov;18(11):1127-1143. doi: 10.1080/14760584.2019.1690458. Epub 2019 Dec 2. Expert Rev Vaccines. 2019. PMID: 31791150 Free PMC article. Review.
Cited by
-
HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6.Virol J. 2022 Sep 7;19(1):143. doi: 10.1186/s12985-022-01876-1. Virol J. 2022. PMID: 36071449 Free PMC article.
-
Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits.Vaccine X. 2022 Sep 30;12:100222. doi: 10.1016/j.jvacx.2022.100222. eCollection 2022 Dec. Vaccine X. 2022. PMID: 36262212 Free PMC article.
-
Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.Retrovirology. 2019 Nov 8;16(1):31. doi: 10.1186/s12977-019-0493-y. Retrovirology. 2019. PMID: 31703699 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials